AI assistant
IDEAYA Biosciences, Inc. — Director's Dealing 2021
Feb 11, 2021
31547_dirs_2021-02-10_50bc6446-08d7-4978-a999-45ffea284052.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEAYA Biosciences, Inc. (IDYA)
CIK: 0001676725
Period of Report: 2021-02-08
Reporting Person: Lackner Mark (SVP, Head of Biology)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-08 | Common Stock | M | 300 | $6.98 | Acquired | 300 | Direct |
| 2021-02-08 | Common Stock | S | 100 | $21.02 | Disposed | 200 | Direct |
| 2021-02-08 | Common Stock | S | 200 | $21 | Disposed | 0 | Direct |
| 2021-02-09 | Common Stock | M | 1104 | $6.98 | Acquired | 1104 | Direct |
| 2021-02-09 | Common Stock | S | 1104 | $21.0456 | Disposed | 0 | Direct |
| 2021-02-10 | Common Stock | M | 596 | $6.98 | Acquired | 596 | Direct |
| 2021-02-10 | Common Stock | S | 596 | $21.00 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-08 | Stock Option (right to buy) | $6.98 | M | 300 | Disposed | 2028-12-11 | Common Stock (300) | Direct |
| 2021-02-09 | Stock Option (right to buy) | $6.98 | M | 1104 | Disposed | 2028-12-11 | Common Stock (1104) | Direct |
| 2021-02-10 | Stock Option (right to buy) | $6.98 | M | 596 | Disposed | 2028-12-11 | Common Stock (596) | Direct |
Footnotes
F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2: This transaction was executed in multiple trades in prices ranging from $21.00 to $21.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.